IPO Year: 2023
Exchange: NASDAQ
SC 13G - Elevai Labs Inc. (0001840563) (Subject)
SC 13D - Elevai Labs Inc. (0001840563) (Subject)
Agreement adds two drug candidates to product pipeline consisting of (i) "EL-22", a clinical stage engineered probiotic expressing myostatin, and (ii) "EL-32", a preclinical engineered probiotic expressing dual myostatin & activin-A.Exclusive license covers global rights excluding South Korea.Clinical and preclinical data supports advancing EL-22, a novel investigational myostatin asset for the treatment of obesity for an investigational new drug "IND" application in 2025. EL-22 has demonstrated significant increase in body weight and restored muscle damage in preclinical mouse models, suggesting potential as a combination to glucagon-like peptide-1 "GLP-1" products to treat obesity. NEWPOR
S-1 - Elevai Labs Inc. (0001840563) (Filer)
DEFR14C - Elevai Labs Inc. (0001840563) (Filer)
8-K - Elevai Labs Inc. (0001840563) (Filer)
DEF 14C - Elevai Labs Inc. (0001840563) (Filer)
8-K - Elevai Labs Inc. (0001840563) (Filer)
8-K - Elevai Labs Inc. (0001840563) (Filer)
PRE 14C - Elevai Labs Inc. (0001840563) (Filer)
PRER14C - Elevai Labs Inc. (0001840563) (Filer)
PRE 14C - Elevai Labs Inc. (0001840563) (Filer)
PRER14C - Elevai Labs Inc. (0001840563) (Filer)
3/A - Elevai Labs Inc. (0001840563) (Issuer)
3/A - Elevai Labs Inc. (0001840563) (Issuer)
Professor of Medicine at the University of California, Los Angeles (UCLA), where he serves as Director of the UCLA Metabolism Research Theme.Over 180 publications in the field of obesity & metabolism, along with multiple NIH-funded projects as Principal Investigator.Dr. Shirihai is a renowned researcher regularly invited as a keynote speaker at annual scientific conferences and has consulted for Johnson & Johnson, Bayer, AstraZeneca and Pfizer, among other healthcare companies. NEWPORT BEACH, Calif., July 30, 2024 (GLOBE NEWSWIRE) -- Elevai Labs Inc. (NASDAQ:ELAB) ("Elevai" or the "Company"), a pioneering force in medical aesthetics, announced the appointment of Orian Shirihai, MD, PhD, t
NEWPORT BEACH, Calif., June 14, 2024 (GLOBE NEWSWIRE) -- Elevai Labs Inc. (NASDAQ:ELAB) ("Elevai" or the "Company"), a pioneering force in medical aesthetics, announced the formation of a new Scientific Advisory Board to support the advancement of EL-22, a first-in-class engineered probiotic approach, to address obesity's pressing issue of preserving muscle while on weight loss treatments, including GLP-1 receptor agonists. "We are honored to be forming a Scientific Advisory Board with renowned members that possess deep and complementary knowledge in metabolic diseases, obesity, weight management, muscle preservation and physical function in addition to significant experience in clinical
Case Studies Highlight Potential of Elevai Exosome Technology in Melasma Care When Used with Laser Therapy. Early Results Show Synergistic Effects of Elevai Exosomes™ and Laser Treatments for Melasma Improvement, With No Recurrence After Six Months. NEWPORT BEACH, Calif., Sept. 10, 2024 (GLOBE NEWSWIRE) -- Elevai Labs, Inc. (NASDAQ:ELAB) ("Elevai" or the "Company"), a pioneering force in medical aesthetics, today announced positive case study results from patients undergoing laser therapy followed by use of Elevai E-Series for applications in melasma. Elevai believes that these case studies can be the premise for future exosome research on effective melasma solutions. Melasma is a commo
On Going Research Study Demonstrates Reversal of Hair Thinning and Inflammation with Elevai Exosomes™.Ongoing Research to Combine Exosome and Mitochondrial Technology for Enhanced Scalp and Hair Vitality. NEWPORT BEACH, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Elevai Labs, Inc. (NASDAQ:ELAB) ("Elevai" or the "Company"), a pioneering force in medical aesthetics, today announced data results from an on-going research study conducted in partnership with Carly Klein, President of the National Hair Loss Medical Aesthetics ("NHLMA"), demonstrating the potential of its proprietary Elevai Exosomes™ in hair restoration. The research study assessed the application of topical Elevai exosomes, in
"One of the Biggest Innovations in Hair Loss We've Seen in Twenty-Five Years" - BosleyMD® Teams With Start-up Yuva Biosciences in National Launch of Breakthrough Technology1Elevai Labs and Yuva Biosciences Join Forces for Breakthrough in Hair and Scalp Care Technology NEWPORT BEACH, Calif., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Elevai Labs, Inc. (NASDAQ:ELAB) ("Elevai" or the "Company"), a pioneering force in medical aesthetics announces the filing of two innovative patents in collaboration with Yuva Biosciences. These patents support the development of Elevai's innovative solutions for hair and scalp vitality. The first patent, "COMPOSITIONS AND METHODS FOR THE TREATMENT OF SKIN, SC
NEWPORT BEACH, Calif., Aug. 26, 2024 (GLOBE NEWSWIRE) -- Elevai Labs, Inc. (NASDAQ:ELAB) ("Elevai" or the "Company"), a pioneering force in medical aesthetics, announces the completion of a clinical study examining the effectiveness of Elevai exosomes on facial appearance. The data, pending peer review, from the clinical study was internally reviewed by the Company, and the results show Elevai enfinity™ to be safe and tolerable with significant improvement noted across many aspects of skin appearance. Elevai aims to publish the full study results in the near future. The study assessed the use of twice-daily Elevai enfinity™, a topical exosome product, on 29 study participants over a 12-we
Preliminary data from the research study in partnership with Dalhousie University demonstrates that Elevai's hUMSC derived exosomes ("ELEVAI exosomes™") contain over 800 proteins that are associated with wound healing, immunomodulation and remodeling of the skin's extracellular matrix ("ECM").ELEVAI exosomes™ protein profile detected as part of this study was statistically significant and notably enriched compared to 54 previously published sets of exosome protein data.Data implies ELEVAI exosomes™ may be a source for proteins that typically decrease with age, and can be important components that prevent skin thinning, loss of elasticity and wrinkle formation. NEWPORT BEACH, Calif., Aug.
NEWPORT BEACH, Calif., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Elevai Labs Inc. (NASDAQ:ELAB) ("Elevai" or the "Company"), a pioneering force in medical aesthetics, today reported financial results for the second quarter ended June 30, 2024 and provided a business update. Financial Results for the Three and Six Months Ended June 30, 2024 Revenue increased to $605,529 for the three months ended June 30, 2024, and $1,220,092 for the six months ended June 30, 2024, an increase of 91.3% and 165.6% respectively year-over-year.Gross margin of 72.5% for the three months ended June 30, 2024, and 72.5% for the six months ended June 30, 2024, compared to 65.8% for the three months ended
Professor of Medicine at the University of California, Los Angeles (UCLA), where he serves as Director of the UCLA Metabolism Research Theme.Over 180 publications in the field of obesity & metabolism, along with multiple NIH-funded projects as Principal Investigator.Dr. Shirihai is a renowned researcher regularly invited as a keynote speaker at annual scientific conferences and has consulted for Johnson & Johnson, Bayer, AstraZeneca and Pfizer, among other healthcare companies. NEWPORT BEACH, Calif., July 30, 2024 (GLOBE NEWSWIRE) -- Elevai Labs Inc. (NASDAQ:ELAB) ("Elevai" or the "Company"), a pioneering force in medical aesthetics, announced the appointment of Orian Shirihai, MD, PhD, t
Elevai is showcasing its new S-Series product line at The Aesthetic Show in Las Vegas, NV.Elevai's hair and scalp solutions combine the power of Exosomes with advanced Mitochondrial Technology. NEWPORT BEACH, Calif., June 28, 2024 (GLOBE NEWSWIRE) -- ELEVAI LABS, INC. (NASDAQ:ELAB), a pioneering force in medical aesthetics, is excited to announce the introduction of the Elevai S-Series™ hair and scalp care product line through Elevai Skincare, a subsidiary of Elevai Labs. The Elevai S-series Root Renewal System™ and the technology behind it will be presented at The Aesthetic Show on June 28th, 2024, held at the Wynn Las Vegas, NV. The Elevai S-Series Root Renewal SystemTM is a three-p
NEWPORT BEACH, Calif., June 26, 2024 (GLOBE NEWSWIRE) -- ELEVAI LABS, INC., (NASDAQ:ELAB) a pioneering force in medical aesthetics, is excited to announce Elevai Skincare's participation in The Aesthetic Show, taking place on June 27-30, 2024 at the Wynn Las Vegas. The company will be showcasing its latest advancements at Booth #511 and unveiling the next generation of its groundbreaking stem cell exosome products. Jordan R. Plews, PhD, the CEO and Co-Founder of Elevai Skincare, will lead a highly anticipated presentation to introduce an innovative new product line. Joining Dr. Plews will be distinguished guest speaker Keshav Singh, PhD, a renowned scientist and inventor of one of the key
NEWPORT BEACH, Calif., June 14, 2024 (GLOBE NEWSWIRE) -- Elevai Labs Inc. (NASDAQ:ELAB) ("Elevai" or the "Company"), a pioneering force in medical aesthetics, announced the formation of a new Scientific Advisory Board to support the advancement of EL-22, a first-in-class engineered probiotic approach, to address obesity's pressing issue of preserving muscle while on weight loss treatments, including GLP-1 receptor agonists. "We are honored to be forming a Scientific Advisory Board with renowned members that possess deep and complementary knowledge in metabolic diseases, obesity, weight management, muscle preservation and physical function in addition to significant experience in clinical
Shares of Indivior PLC (NASDAQ:INDV) rose sharply in today's pre-market trading after the company posted better-than-expected second-quarter results and announced an accelerated $100 million share repurchase program. Indivior reported quarterly earnings of 44 cents per share which beat the analyst consensus estimate of 14 cents per share. The company reported quarterly sales of $299.00 million which beat the analyst consensus estimate of $296.05 million. Indivior shares jumped 14.5% to $12.46 in pre-market trading. Here are some other stocks moving in pre-market trading. Gainers Psyence Biomedical Ltd. (NASDAQ:PBM) rose 157.4% to $1.00 in pre-market trading after the company
The most oversold stocks in the consumer staples sector presents an opportunity to buy into undervalued companies. ` The RSI is a momentum indicator, which compares a stock’s strength on days when prices go up to its strength on days when prices go down. When compared to a stock’s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the RSI is below 30, according to Benzinga Pro. Here's the latest list of major oversold players in this sector, having an RSI near or below 30. African Agriculture Holdings Inc (NASDAQ:AAGR) On Feb. 6, African Agriculture named Michael Rhodes as Chief Executive
Elevai Labs Inc. (NASDAQ:ELAB) ("Elevai" or the "Company"), a pioneering force in medical aesthetics, announced the formation of a new Scientific Advisory Board to support the advancement of EL-22, a first-in-class engineered probiotic approach, to address obesity's pressing issue of preserving muscle while on weight loss treatments, including GLP-1 receptor agonists.
Elevai Labs (NASDAQ:ELAB) reported quarterly losses of $(0.08) per share. This is a 27.03 percent increase over losses of $(0.11) per share from the same period last year. The company reported $614.56 thousand in sales this quarter. This is a 330.31 percent increase over sales of $142.82 thousand the same period last year.
Preclinical results of EL-22 from a 2022 study demonstrated physiological (serum creatine kinase level), physical (body weight change), and functional (rotarod test) improvements in the dystrophic features of mdx mice, a mouse model of Duchenne muscular dystrophy (DMD)1.Elevai believes that EL-22 has the potential to treat obesity in combination with popular weight loss therapeutics, including GLP-1 receptor agonists, by preserving muscle mass while decreasing fat mass.Elevai plans to submit an Investigational New Drug (IND) application in 2025 that utilizes the licensed asset EL-22, previously called BLS-M221. NEWPORT BEACH, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- Elevai Labs, Inc. (NASDAQ
Gainers Elevai Labs (NASDAQ:ELAB) shares rose 22.7% to $0.8 during Wednesday's after-market session. The company's market cap stands at $13.8 million. Vintage Wine Estates (NASDAQ:VWE) shares rose 4.99% to $0.24. The market value of their outstanding shares is at $14.5 million. Herbalife (NYSE:HLF) shares moved upwards by 4.52% to $9.07. The market value of their outstanding shares is at $905.3 million. As per the press release, Q1 earnings came out today. Edible Garden AG (NASDAQ:EDBL) shares rose 4.08% to $5.1. The company's market cap stands at $1.5 million. Sprouts Farmers Market (NASDAQ:SFM) stock moved upwards by 3.81% to $66.74. The company's market cap stands at $6.7 billion. As